Loading
The 2022 fast-track amendment in which the US oncology society added pembrolizumab before and after surgery for high-risk early triple-negative breast cancer, a year after its main guideline had said the evidence was insufficient.
ASCO Rapid Recommendation Update by Korde, Somerfield, Hershman and the neoadjuvant therapy guideline expert panel. Rapid updates highlight revisions to selected ASCO guideline recommendations in response to new, practice-changing data, are supported by an evidence review and follow the ASCO Guideline Methodology Manual; their goal is to disseminate updated recommendations quickly. This update responded to the KEYNOTE-522 event-free survival result and the July 2021 US approval of pembrolizumab with chemotherapy as neoadjuvant treatment, continued as a single agent after surgery, for high-risk early-stage triple-negative breast cancer.
Shows how quickly the standard moved: the 2021 guideline and its reversal are 15 months apart.
Shares American Society of Clinical Oncology (ASCO), Triple-negative breast cancer roadmap: from a remainder defined by three negative tests to immunotherapy, antibody-drug conjugates and the residual disease problem, Journal of Clinical Oncology, Triple-negative breast cancer (TNBC) and the tag tnbc-evidence.
Shares KEYNOTE-522, Triple-negative breast cancer roadmap: from a remainder defined by three negative tests to immunotherapy, antibody-drug conjugates and the residual disease problem, Pembrolizumab, Triple-negative breast cancer (TNBC) and the tag tnbc-evidence.
Shares OptimICE-pCR (A012103), KEYNOTE-522, Triple-negative breast cancer roadmap: from a remainder defined by three negative tests to immunotherapy, antibody-drug conjugates and the residual disease problem, Pembrolizumab and the tag tnbc-evidence.
Shares KEYNOTE-522, Triple-negative breast cancer roadmap: from a remainder defined by three negative tests to immunotherapy, antibody-drug conjugates and the residual disease problem, Journal of Clinical Oncology, Triple-negative breast cancer (TNBC) and the tag tnbc-evidence.
Shares Triple-negative breast cancer roadmap: from a remainder defined by three negative tests to immunotherapy, antibody-drug conjugates and the residual disease problem, Journal of Clinical Oncology, Triple-negative breast cancer (TNBC) and the tag tnbc-evidence.
Shares KEYNOTE-522, Triple-negative breast cancer roadmap: from a remainder defined by three negative tests to immunotherapy, antibody-drug conjugates and the residual disease problem, Triple-negative breast cancer (TNBC) and the tag tnbc-evidence.
Shares American Society of Clinical Oncology (ASCO), Triple-negative breast cancer roadmap: from a remainder defined by three negative tests to immunotherapy, antibody-drug conjugates and the residual disease problem, Pembrolizumab, Triple-negative breast cancer (TNBC) and the tag tnbc-evidence.
Shares KEYNOTE-522, Triple-negative breast cancer roadmap: from a remainder defined by three negative tests to immunotherapy, antibody-drug conjugates and the residual disease problem, Triple-negative breast cancer (TNBC) and the tag tnbc-evidence.